ArticleCureus2025
Lipid Parameters and Their Association With Liver Function Test Variables in Patients With Type 2 Diabetes Mellitus.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aim To assess the prevalence of elevated liver enzymes and their correlation with lipid profile abnormalities in patients with type 2 diabetes mellitus (T2DM). Method A total of 130 individuals with diabetes were enrolled in the study, and blood serum samples were collected to evaluate liver function tests and lipid profiles. The association between liver enzyme levels and T2DM was analyzed using logistic regression. Results Altered liver enzymes were observed in 40 cases (30.77%), while lipid abnormalities were noted in 92 cases (70.76%) in T2DM cases. Among liver function parameters, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) exhibited the greatest degree of variation. AST showed significant correlations with total cholesterol (r = 0.513), triglycerides (r = 0.530), low-density lipoprotein (LDL) (r = 0.518), diabetes duration (r = 0.198), and high-density lipoprotein (HDL) (r = -0.288). Similarly, ALT showed significant correlations with all lipid profile parameters. Logistic regression analysis revealed that abnormal levels of total cholesterol (OR: 1.452, p < 0.0001; 95% CI: 1.29-1.62), LDL (OR: 1.59, p < 0.0001; 95% CI: 0.41-0.69), and triglycerides (OR: 1.798, p < 0.0001; 95% CI: 1.699-2.12) were independently associated with type 2 diabetes mellitus. Receiver operating characteristic (ROC) curve analysis showed that ALT had an AUROC of 0.86 in predicting non-alcoholic fatty liver disease (NAFLD) among diabetic patients. There was a strong correlation between abnormal liver enzymes, and dyslipidemia, with odds ratio analysis indicating an increased risk of liver disorders in individuals with poor diabetic control. Liver function abnormalities frequently coexist with altered lipid profiles in patients with T2DM. Conclusion Consistent monitoring of lipid profile levels in patients with T2DM may aid in preventing cardiovascular complications. Follow-up using laboratory parameters such as Fibrosis-4 (FIB-4) scores and elastography is recommended to monitor patients with fatty liver disease, as these variables can detect early hepatic changes, advanced fibrosis, and other liver abnormalities. Regular screening for metabolic dysfunction-associated steatotic liver disease (MASLD) may be warranted in diabetic patients with elevated liver enzymes, potentially facilitating early intervention and reducing the risk of cirrhosis and its related complications.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.